AU2014250937A1 - Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction - Google Patents
Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction Download PDFInfo
- Publication number
- AU2014250937A1 AU2014250937A1 AU2014250937A AU2014250937A AU2014250937A1 AU 2014250937 A1 AU2014250937 A1 AU 2014250937A1 AU 2014250937 A AU2014250937 A AU 2014250937A AU 2014250937 A AU2014250937 A AU 2014250937A AU 2014250937 A1 AU2014250937 A1 AU 2014250937A1
- Authority
- AU
- Australia
- Prior art keywords
- bimatoprost
- composition
- fat
- sustained release
- reduction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000013268 sustained release Methods 0.000 title claims abstract description 35
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 35
- 230000009467 reduction Effects 0.000 title claims abstract description 28
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 title claims description 73
- 229960002470 bimatoprost Drugs 0.000 title claims description 64
- 150000003180 prostaglandins Chemical class 0.000 title claims description 23
- 229940094443 oxytocics prostaglandins Drugs 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 claims abstract description 84
- 238000000034 method Methods 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 238000002347 injection Methods 0.000 claims abstract description 17
- 239000007924 injection Substances 0.000 claims abstract description 17
- 238000009472 formulation Methods 0.000 claims description 31
- 239000007943 implant Substances 0.000 claims description 26
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical class CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 20
- 229960001160 latanoprost Drugs 0.000 claims description 20
- 238000012384 transportation and delivery Methods 0.000 claims description 20
- 239000004005 microsphere Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 12
- 229920002674 hyaluronan Polymers 0.000 claims description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 10
- 229960003160 hyaluronic acid Drugs 0.000 claims description 10
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical class CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 9
- 229960002368 travoprost Drugs 0.000 claims description 9
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 claims description 7
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 210000004003 subcutaneous fat Anatomy 0.000 claims description 6
- LLKFNPUXQZHIAE-UHFFFAOYSA-N 5-(3-aminopropyl)-8-bromo-3-methyl-2h-pyrazolo[4,3-c]quinolin-4-one Chemical compound O=C1N(CCCN)C2=CC=C(Br)C=C2C2=C1C(C)=NN2 LLKFNPUXQZHIAE-UHFFFAOYSA-N 0.000 claims description 5
- 206010003694 Atrophy Diseases 0.000 claims description 5
- 210000000579 abdominal fat Anatomy 0.000 claims description 5
- 230000037444 atrophy Effects 0.000 claims description 5
- 210000001789 adipocyte Anatomy 0.000 claims description 3
- 210000001593 brown adipocyte Anatomy 0.000 claims description 2
- 210000000636 white adipocyte Anatomy 0.000 claims description 2
- -1 poly(caprolactone) Polymers 0.000 description 19
- 239000000499 gel Substances 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- 229910052688 Gadolinium Inorganic materials 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001610 polycaprolactone Polymers 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000117 poly(dioxanone) Polymers 0.000 description 2
- 239000002745 poly(ortho ester) Substances 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 229920000428 triblock copolymer Polymers 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 description 1
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 description 1
- 239000001797 sucrose acetate isobutyrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000001248 thermal gelation Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- YZWRNSARCRTXDS-UHFFFAOYSA-N tripropionin Chemical compound CCC(=O)OCC(OC(=O)CC)COC(=O)CC YZWRNSARCRTXDS-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019203214A AU2019203214B2 (en) | 2013-04-12 | 2019-05-08 | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361811682P | 2013-04-12 | 2013-04-12 | |
| US61/811,682 | 2013-04-12 | ||
| PCT/US2014/033558 WO2014169075A1 (en) | 2013-04-12 | 2014-04-09 | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019203214A Division AU2019203214B2 (en) | 2013-04-12 | 2019-05-08 | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2014250937A1 true AU2014250937A1 (en) | 2015-10-22 |
Family
ID=51686960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014250937A Abandoned AU2014250937A1 (en) | 2013-04-12 | 2014-04-09 | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
| AU2019203214A Ceased AU2019203214B2 (en) | 2013-04-12 | 2019-05-08 | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019203214A Ceased AU2019203214B2 (en) | 2013-04-12 | 2019-05-08 | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140308354A1 (enExample) |
| EP (2) | EP2983663B1 (enExample) |
| JP (1) | JP2016520561A (enExample) |
| KR (1) | KR20150141972A (enExample) |
| CN (2) | CN110840899A (enExample) |
| AU (2) | AU2014250937A1 (enExample) |
| BR (1) | BR112015025915A8 (enExample) |
| CA (1) | CA2908731A1 (enExample) |
| CL (1) | CL2015003023A1 (enExample) |
| DK (1) | DK2983663T3 (enExample) |
| ES (1) | ES2785382T3 (enExample) |
| IL (1) | IL242006B (enExample) |
| MX (1) | MX381097B (enExample) |
| MY (1) | MY187802A (enExample) |
| RU (1) | RU2015143859A (enExample) |
| SG (2) | SG10201701938PA (enExample) |
| WO (1) | WO2014169075A1 (enExample) |
| ZA (1) | ZA201507217B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017023316A2 (pt) * | 2015-04-30 | 2018-08-14 | Allergan, Inc. | método cosmético e uso terapêutico para redução de gordura |
| US11452703B2 (en) * | 2020-05-21 | 2022-09-27 | Peregrine Ophthalmic PTE LTD. | Methods and compositions for reducing adipocyte numbers |
| US12004995B2 (en) * | 2020-07-21 | 2024-06-11 | Allergan, Inc. | Intraocular implant with high loading of a prostamide |
| AU2024258544A1 (en) * | 2023-04-18 | 2025-09-04 | Welfare Concepts Limited | Composition and method for inducing luteolysis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2218424A (en) * | 1931-05-07 | 1940-10-15 | Teleregister Corp | Transmitter and code translator |
| US4525359A (en) * | 1982-12-10 | 1985-06-25 | Greenway Frank L Iii | Treatment for selective weight control |
| US6124344A (en) | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| EP0825980B1 (en) * | 1995-05-18 | 2001-07-04 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylakenyl derivatives as therapeutic agents for the treatment of ocular hypertension |
| US8114911B2 (en) | 2002-10-23 | 2012-02-14 | Sucampo Ag | Prostaglandin compounds for the treatment of obesity |
| KR20050085367A (ko) * | 2002-12-04 | 2005-08-29 | 산텐 세이야꾸 가부시키가이샤 | 결막하 데포에 의한 약물 송달 시스템 |
| EP1699432A2 (en) * | 2003-12-22 | 2006-09-13 | Aventis Pharmaceuticals, Inc. | Injectable phosphatidylcholine preparations |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| US7666912B2 (en) | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
| PL2077830T3 (pl) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
| US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US9095506B2 (en) * | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| US20130071349A1 (en) * | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
| US20120022137A1 (en) | 2010-07-21 | 2012-01-26 | Rivers Hongwen M | METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS |
| EP2968668B1 (en) * | 2013-03-15 | 2019-07-03 | Allergan, Inc. | Prostamide-containing intraocular implant |
| BR112017023316A2 (pt) | 2015-04-30 | 2018-08-14 | Allergan, Inc. | método cosmético e uso terapêutico para redução de gordura |
-
2014
- 2014-04-09 EP EP14725582.2A patent/EP2983663B1/en active Active
- 2014-04-09 MX MX2015014320A patent/MX381097B/es unknown
- 2014-04-09 WO PCT/US2014/033558 patent/WO2014169075A1/en not_active Ceased
- 2014-04-09 JP JP2016507645A patent/JP2016520561A/ja active Pending
- 2014-04-09 SG SG10201701938PA patent/SG10201701938PA/en unknown
- 2014-04-09 CA CA2908731A patent/CA2908731A1/en not_active Abandoned
- 2014-04-09 ES ES14725582T patent/ES2785382T3/es active Active
- 2014-04-09 US US14/248,898 patent/US20140308354A1/en not_active Abandoned
- 2014-04-09 KR KR1020157029970A patent/KR20150141972A/ko not_active Ceased
- 2014-04-09 AU AU2014250937A patent/AU2014250937A1/en not_active Abandoned
- 2014-04-09 EP EP20152147.3A patent/EP3656375A1/en not_active Withdrawn
- 2014-04-09 CN CN201910977574.7A patent/CN110840899A/zh active Pending
- 2014-04-09 MY MYPI2015002531A patent/MY187802A/en unknown
- 2014-04-09 SG SG10202109919P patent/SG10202109919PA/en unknown
- 2014-04-09 BR BR112015025915A patent/BR112015025915A8/pt active Search and Examination
- 2014-04-09 CN CN201480020790.8A patent/CN105101962A/zh active Pending
- 2014-04-09 DK DK14725582.2T patent/DK2983663T3/da active
- 2014-04-09 RU RU2015143859A patent/RU2015143859A/ru not_active Application Discontinuation
-
2015
- 2015-09-29 ZA ZA2015/07217A patent/ZA201507217B/en unknown
- 2015-10-09 CL CL2015003023A patent/CL2015003023A1/es unknown
- 2015-10-11 IL IL242006A patent/IL242006B/en active IP Right Grant
-
2016
- 2016-04-21 US US15/134,792 patent/US10682361B2/en active Active
-
2019
- 2019-05-08 AU AU2019203214A patent/AU2019203214B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3656375A1 (en) | 2020-05-27 |
| CN105101962A (zh) | 2015-11-25 |
| RU2015143859A (ru) | 2017-05-16 |
| BR112015025915A2 (pt) | 2017-07-25 |
| US20140308354A1 (en) | 2014-10-16 |
| HK1221406A1 (en) | 2017-06-02 |
| KR20150141972A (ko) | 2015-12-21 |
| RU2015143859A3 (enExample) | 2018-03-05 |
| IL242006B (en) | 2020-04-30 |
| WO2014169075A1 (en) | 2014-10-16 |
| MX381097B (es) | 2025-03-12 |
| EP2983663A1 (en) | 2016-02-17 |
| CN110840899A (zh) | 2020-02-28 |
| DK2983663T3 (da) | 2020-04-20 |
| US20160339039A1 (en) | 2016-11-24 |
| MX2015014320A (es) | 2015-12-08 |
| US10682361B2 (en) | 2020-06-16 |
| MY187802A (en) | 2021-10-26 |
| BR112015025915A8 (pt) | 2020-01-14 |
| SG10202109919PA (en) | 2021-10-28 |
| CA2908731A1 (en) | 2014-10-16 |
| AU2019203214B2 (en) | 2020-10-29 |
| JP2016520561A (ja) | 2016-07-14 |
| ES2785382T3 (es) | 2020-10-06 |
| SG10201701938PA (en) | 2017-04-27 |
| EP2983663B1 (en) | 2020-01-22 |
| ZA201507217B (en) | 2017-09-27 |
| NZ712804A (en) | 2021-02-26 |
| AU2019203214A1 (en) | 2019-05-30 |
| CL2015003023A1 (es) | 2016-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kempe et al. | In situ forming implants—an attractive formulation principle for parenteral depot formulations | |
| AU2019203214B2 (en) | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction | |
| EP1581181B1 (en) | Controlled release depot formulations | |
| US20040109893A1 (en) | Sustained release dosage forms of anesthetics for pain management | |
| EP2067468A1 (en) | Sustained release dosage forms of anesthetics for pain management | |
| JP2005538107A5 (ja) | 注入可能な多モードポリマーのデポ組成物及びその使用 | |
| US20210361292A1 (en) | Methods for in situ formed nerve cap with rapid release | |
| Nguyen et al. | Design and translation of injectable biomaterials | |
| CA3163429A1 (en) | Methods and devices for in situ formed nerve cap with rapid release | |
| NZ574443A (en) | Short duration depot formulations | |
| JP2016520561A5 (enExample) | ||
| Ito et al. | Application of calcium phosphate as a controlled-release device | |
| HK40031326A (en) | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction | |
| HK40025309A (en) | Subtained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction | |
| NZ712804B2 (en) | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction | |
| HK1221406B (en) | Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction | |
| EP3986491B1 (en) | Crosslinkable hydrogel compositions | |
| CN118697697B (zh) | 一种脂质体封装的长效罗哌卡因缓释系统 | |
| Boesel et al. | Injectable biodegradable systems | |
| KR20230022737A (ko) | 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트 | |
| TW202126321A (zh) | 用於延長遞送以肽類為活性醫藥成分之液體聚合物組合物及系統 | |
| Pawar et al. | 17 Injectable Polymers for Regional Drug Delivery | |
| Osmani et al. | In-situ Forming Parenteral Drug Delivery: A New-fangled Loom In |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |